ArticleClinical journal of gastroenterology2026
Durable complete response following sequential atezolizumab-bevacizumab and delayed transcatheter arterial embolization in advanced hepatocellular carcinoma.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atezolizumab plus bevacizumab (ATZ/BEV) is an established first-line therapy for advanced hepatocellular carcinoma (HCC); however, complete response (CR) is rare. A man in his 70s was diagnosed with unresectable, multifocal HCC (maximum diameter, 190 mm) with vascular invasion. Liver function was preserved (Child-Pugh A, ALBI grade 1). ATZ/BEV was initiated, but the second cycle was postponed due to adverse events and intratumoral hemorrhage. Eight weeks later, selective transcatheter arterial embolization (TAE) was performed. Follow-up imaging showed disappearance of arterial enhancement in both embolized and non-embolized lesions. The patient has maintained CR for three years without additional treatment following sequential ATZ/BEV and selective TAE.
Indexed as
Identifiers
42696201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.